Tatsuro Kosaka - Chugai Pharmaceutical President, COO and Representative Director
| CHGCY Stock | USD 16.79 0.15 0.90% |
President
Mr. Tatsuro Kosaka was serving as President, Chief Executive Officer and Representative Director in Chugai Pharmaceutical Co., Ltd. since March 2018. He is also serving as Independent Director in Asahi Group Holdings, Ltd. He joined the Company in April 1976. His previous titles include Director of Medical Business Strategy, Director of Business Planning, Deputy Chief Senior Director of Sales, Manager of Strategy Marketing Unit, Manager of Life Circle Management and Marketing Unit, Executive Officer, Managing Executive Officer, Senior Managing Executive Officer and Chief Operating Officer in the Company. He used to serve as Vice President in a subsidiary, Chugai Pharma Europe Ltd. . since 2018.
| Age | 65 |
| Tenure | 6 years |
| Phone | 81 3 3281 6611 |
| Web | https://www.chugai-pharm.co.jp |
Chugai Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.1956 % which means that it generated a profit of $0.1956 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2867 %, meaning that it generated $0.2867 on every $100 dollars invested by stockholders. Chugai Pharmaceutical's management efficiency ratios could be used to measure how well Chugai Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Joseph Wolk | Johnson Johnson | 54 | |
| Kathryn Wengel | Johnson Johnson | 55 | |
| Kathy Wengel | Johnson Johnson | N/A | |
| Enrique Conterno | Eli Lilly and | 51 | |
| Sanat Chattopadhyay | Merck Company | 61 | |
| Anne White | Eli Lilly and | 55 | |
| Ruud Dobber | AstraZeneca PLC ADR | N/A | |
| Alfonso Zulueta | Eli Lilly and | 57 | |
| Mark Fishman | Novartis AG ADR | 63 | |
| Caroline Litchfield | Merck Company | 55 | |
| Leon Wang | AstraZeneca PLC ADR | N/A | |
| Michael Rosenblatt | Merck Company | 67 | |
| Pam Cheng | AstraZeneca PLC ADR | 54 | |
| Willie Deese | Merck Company | 59 | |
| Sean Bohen | AstraZeneca PLC ADR | N/A | |
| Fiona Marshall | Novartis AG ADR | 60 | |
| Adam Schechter | Merck Company | 52 | |
| Mirian GraddickWeir | Merck Company | 62 | |
| Frank Clyburn | Merck Company | 54 | |
| Andre Wyss | Novartis AG ADR | 50 | |
| Ashley Watson | Merck Company | 48 | |
Management Performance
Chugai Pharmaceutical Leadership Team
Elected by the shareholders, the Chugai Pharmaceutical's board of directors comprises two types of representatives: Chugai Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chugai. The board's role is to monitor Chugai Pharmaceutical's management team and ensure that shareholders' interests are well served. Chugai Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chugai Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Osamu Nagayama, Chairman and CEO | ||
| Masayuki Oku, Independent Director | ||
| Franz Humer, Independent Director | ||
| Sophie KornowskiBonnet, Independent Director | ||
| Yasuo Ikeda, Independent Director | ||
| Harunori Yamazaki, Manager of Accounting Group in Finance & Accounting Unit | ||
| Yoshiyuki Yano, Executive Officer, Director of Human Resources | ||
| William Anderson, Director | ||
| Tatsuro Kosaka, President, COO and Representative Director | ||
| Motoo Ueno, Vice Chairman of the Board, Representative Director | ||
| Toshihiko Komori, Executive Officer, Assistant Manager of Project & Life Cycle Management Unit, Director of R&D Portfolio | ||
| Mamoru Togashi, Executive Officer, Director of Human Resources, Senior Manager of Human Resources Division | ||
| James Sabry, Director | ||
| Yutaka Tanaka, Managing Executive Officer, Manager of Life Circle Management and Marketing Unit | ||
| Daniel ODay, Independent Director | ||
| Minoru Watanabe, Executive Officer, Director of Business Planning | ||
| Tadahiko Sato, Executive Officer, Senior Manager of Tokyo 1st Office | ||
| Shinji Hidaka, Executive Officer, Deputy Chief Director of Sales, Manager of Primary Unit | ||
| Tetsuya Yamaguchi, Executive Officer, Director of Business Development | ||
| Hitoshi Kuboniwa, Executive Officer, Chief Director of Pharmaceutics Producing | ||
| Masaaki Tohaya, Managing Executive Officer, Chief Director of Sales | ||
| Tsunanori Sato, Executive Officer, Chief Director of Sales | ||
| Toshiaki Itagaki, VP and General Manager of Fin. and Accounting Department | ||
| Junichi Ebihara, VP and General Manager of Legal Department | ||
| Toshiya Sasai, Exec Department | ||
| Koichi Nishikawa, Executive Officer, Deputy Chief Director of Sales, Director of Marketing Planning | ||
| Osamu Okuda, Executive Officer, Director of Business Planning | ||
| Yoshiaki Ohashi, Executive Officer, Chief Director of Drug Safety, Manager of Regulatory & Quality Management Unit | ||
| Yoko Kitagawa, Manager of Consolidated Financial Group in Finance & Accounting Unit | ||
| Christoph Franz, Director | ||
| Shinya Unno, Managing Executive Officer, Director of Business Planning | ||
| Hiroyuki Matsumoto, Executive Officer, Senior Manager of South Kanto Office in Main Sales Unit | ||
| Satoko Shisai, Executive Officer, Senior Manager of IT | ||
| Keiji Kono, Executive Officer, Senior Manager of IT Division | ||
| Hisafumi Okabe, VP and General Manager of Research Division | ||
| Hisanori Takanashi, Executive Officer, Chief Director of Clinical Development | ||
| Hiroshi Murata, Executive Officer, Chief Director of Pharmaceutical Technology | ||
| Yoichiro Ichimaru, Independent Director | ||
| Yoshio Itaya, CFO, Executive VP, General Manager of Fin. Supervisory Division and Director | ||
| Masahiko Uchida, Gen Department | ||
| Yasushi Ito, Executive Officer, Chief Director of Clinical Development | ||
| Susumu Kato, Executive Officer, Senior Manager of Tokyo First Office | ||
| Mitsuru Kikuchi, Managing Executive Officer, Director of External Investigation |
Chugai Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Chugai Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.29 | |||
| Return On Asset | 0.2 | |||
| Profit Margin | 0.30 % | |||
| Operating Margin | 0.42 % | |||
| Current Valuation | 39.67 B | |||
| Shares Outstanding | 3.29 B | |||
| Price To Earning | 22.15 X | |||
| Price To Book | 4.62 X | |||
| Price To Sales | 0.04 X | |||
| Revenue | 999.76 B |
Pair Trading with Chugai Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chugai Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chugai Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving together with Chugai Pink Sheet
| 0.72 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
Moving against Chugai Pink Sheet
| 0.53 | JPHLF | Japan Post Holdings | PairCorr |
| 0.5 | JPSTF | JAPAN POST BANK | PairCorr |
The ability to find closely correlated positions to Chugai Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Chugai Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Chugai Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Chugai Pharmaceutical Co to buy it.
The correlation of Chugai Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Chugai Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Chugai Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Chugai Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chugai Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Chugai Pharmaceutical information on this page should be used as a complementary analysis to other Chugai Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Chugai Pink Sheet analysis
When running Chugai Pharmaceutical's price analysis, check to measure Chugai Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chugai Pharmaceutical is operating at the current time. Most of Chugai Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Chugai Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chugai Pharmaceutical's price. Additionally, you may evaluate how the addition of Chugai Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |